


RECEIVED



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
F.G	148	4,269,857	5/1981	Tokuda et al.	424	325	
N	149	5,221,746	6/1993	Partis et al.	546	220	
N	150	5,264,356	11/1993	Rohrschneider	435	236	
N	151	5,622,972	4/1997	Bryant et al.	514	315	
N	152	5,703,058	12/1997	Schinazi et al.	514	45	
N	153	6,093,702	7/2000	Malley et al.	514	45	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
F.G	154	2,700,267	1/1993	FR	A61K	9/107		
N	155	0 401 194	6/1990	EPO	A61K	31/70		
N	156	0 477 160	9/1991	EPO	C12P	17/04		
N	157	0 691 327	3/1994	EPO	C07C	217/28		
N	158	0 729 747	2/1996	EPO	A61K	7/48		
N	159	WO91/17145	11/1991	PCT	C07D	211/46		
N	160	WO94/04546	3/1994	PCT	C07H	17/02		Abstract
N	161	WO99/29321	6/1999	PCT	A61K	31/445		
N	162	WO99/40916	8/1999	PCT	A61K	31/445		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

F.G	163	Acosta, et al., "Agents for Treating Human Immunodeficiency Virus Infection," Am. J. Hosp. Pharm., Vol. 51, September 15, 1994, pp. 2251-2287
N	164	Tennant, et al., "Animal Models in the Preclinical Assessment of Therapy for Viral Hepatitis," Antiviral Therapy, Vol. 1, (Suppl. 4), 1996, pp. 47-52
N	165	Sachs, "Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than with Azidothymidine," Arch. Inter. Med., Vol. 152, March 1992, pp. 485-501

EXAMINER

Fariba Chashghaei

DATE CONSIDERED

8/30/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 2 of 3

APPLICANT
Richard A. Mueller et al.

FILING DATE GROUP
February 12, 1999 1614

F.G	166	Gasparini, et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, Vol. 13, No. 3, March 1995, pp. 765-782
"	167	Bruyneel, et al. "Effect of Glycosylation Inhibitors on N-Glycosylpeptides and on Invasion of Malignant Mouse MO ₄ Cells in Vitro," Journal of Cell Science, Vol. 95, 1990, pp. 279-286
"	168	Jacob, "Glycosylation Inhibitors in Biology and Medicine," Current Opinion in Structural Biology, No. 5, 1995, pp. 605-611
"	169	Senuma, et al., "Highly Effective Resolution of 1,3-Dibenzyl-6-hydroxy-3,3a,6,6a-tetrahydro-1H-furo[3,4-d]imidazole-2,4-dione, an Intermediate for Biotin, with Optically Active Amines and Reutilization of the Unwanted Epimer," Chem. Pharm. Bull., Vol. 38, No. 4, 1990, pp. 882-887
"	170	Zitzmann, et al., "Imino Sugars Inhibit the Formation and Secretion of Bovine Viral Diarrhea Virus, a Pestivirus Model of Hepatitis C Virus: Implications for the Development of Broad Spectrum Anti-Hepatitis Virus Agents," PNAS, Vol. 96, No. 21, October 12, 1999, pp. 11878-11882
"	171	Jacob, et al., "Iminosugar alpha-Glucosidase Inhibitors as Drugs and Pro-Drugs for Treatment of HIV Infections," Washington Book of Abstracts, 208th ACS National Meeting, August 21-25, 1994, one page
"	172	Rusconi, et al., "Inhibition of Human Immunodeficiency Virus Type I Replication in Cytokine-Stimulated Monocytes/Macrophages by Combination Therapy," Journal of Infectious Diseases, Vol. 170, 1994, pp. 1361-1366
"	173	Goss, et al., "Inhibitors of Carbohydrate Processing: A New Class of Anticancer Agents," Clinical Cancer Research, Vol. 1, September 1995, pp. 935-944
"	174	Isom, et al., "Molecular Pathology of Human Oncogenic Viruses," Cellular and Molecular Pathogenesis, Chapter 14, 1996, pp. 341-387
"	175	Platt, et al., "Modulation of Cell-Surface Transferrin Receptor by the Imino Sugar N-butyldeoxynojirimycin," 1992, Eur. J. Biochem., Vol. 208, pp 187-193
"	176	Kawakami, et al., "Monoclonal Antibodies with Affinity to Self-Complementary Left-Handed DNA Containing Cyclonucleosides with High Anti Conformation," 1994, Nucleosides & Nucleotides, Vol. 13(1-3), pp. 421-427
"	177	Dicato, et al., "Multidrug Resistance: Molecular and Clinical Aspects," 1997, Cytokines, Cellular & Molecular Therapy, Vol. 3, No. 2, pp. 91-100
"	178	Ratner, et al., "Mechanism of Action of N-Butyl Deoxynojirimycin in Inhibiting HIV-1 Infection and Activity in Combination with Nucleoside Analogs," AIDS Research and Human Retroviruses, Vol. 9, No. 4, 1993, pp. 291-297
"	179	Myers, "New Antiretroviral Agents in the Clinic," Reviews of Infectious Diseases, Vol. 12, No. 5, September/October 1990, pp. 944-950
"	180	Yangco, et al., "Pilot Safety and Efficacy of Combination SC-48334 (N-Butyl-Deoxynojirimycin (NB-DNJ) and Zidovudine (ZDA) in Symptomatic HIV-1 Infected Patients with ≥ 200 - ≤ 500 CD4 Cells/mm ³ ," Abstracts of the 1st National Conference on Human Retroviruses, Session 86, Abstract No. 574, p. 160
"	181	Mitts, et al., "The Reaction of Glucose with Some Amines," Journal of the American Chemical Society, Vol. 66, March 1944, pp. 483-486

EXAMINER <i>Fariba Ghashghaee</i>	DATE CONSIDERED <i>8,30,01</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 3 of 3

F.G	182	Fischl, et al., "The Preliminary Efficacy and Safety of N-Butyl-Deoxynojirimycin (SC-48334), an alpha-Glucosidase I Inhibitor, in Combination with Zidovudine (ZDA)," International Conference on AIDS, Berlin, June 6-11, 1993, one page
//	183	Fiume, et al., "Targeting of Antiviral Drugs to the Liver Using Glycoprotein Carriers," Advanced Drug Delivery Reviews, Vol. 14, 1994, pp. 51-65
//	184	Mutchnick, et al., "Thymosin α , Treatment of Chronic Hepatitis B: A Multicenter, Randomized, Placebo-Controlled Double Blind Study," April 1995, AASLD, A1127, one page
//	185	Jones, et al., "Use of the Topliss Scheme for the Design of More Effective Chelating Agents for Cadmium Decorporation," Chem. Res. Toxicol., Vol. 1, 1988, pp. 234-237
//	186	Karrer, et al., "Zur Kenntnis der Reduktionsprodukte aus Aromatischen Aminen und Zuckern," 1935, p. 1338-1340

EXAMINER

Fariba Ghoshghare

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900